Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
Published 5 months ago
Description
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.